Non-syndromic Multifocal Low-Grade Oncocytic Renal Tumors, Including Microtumors, in End-Stage Renal Disease Kidneys with Synchronous Non-TSC Renal Cell Neoplasms
- 16 January 2026
- journal article
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 34 (4) , 1050-1057
Abstract
Low-grade oncocytic tumor (LOT) is a recently described indolent renal neoplasm with over 80% of tumors harboring mutations in the TSC/MTOR signaling pathway. Typically, LOTs present as sporadic solitary tumors in patients with normal renal function, and occasionally in patients with end-stage kidney disease. However, multifocal LOTs have rarely been observed in patients with tuberous sclerosis complex (TSC). We report four patients with multifocal LOTs, including microtumors, coexisting with other renal cell neoplasms in the context of chronic kidney disease (CKD) or end stage renal disease (ESRD) in the absence of clinical features of TSC. Notably, one patient had bilateral, multifocal LOTs alongside synchronous acquired cystic disease-associated renal cell carcinoma (ACD-RCC); while two other patients had concurrent clear cell papillary renal cell tumor (CCPRCT), one with multifocal and the other with solitary LOT; the remaining patient had both coexisting CCPRCT and ACD-RCC as well as multifocal LOT. This series highlights that multifocal LOTs, including microtumors, can be seen in the setting of ESRD and can arise independently of hereditary TSC. The co-occurrence with other ESRD-associated neoplasms underscores the need for broader recognition of LOT within this clinical context.Keywords
This publication has 27 references indexed in Scilit:
- L1 Cell Adhesion Molecule (L1CAM) Expression and Molecular Alterations Distinguish Low-Grade Oncocytic Tumor From Eosinophilic Chromophobe Renal Cell CarcinomaLaboratory Investigation, 2024
- Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOTVirchows Archiv, 2023
- GPNMB expression identifies TSC1/2/mTOR‐associated and MiT family translocation‐driven renal neoplasmsThe Journal of Pathology, 2022
- Low-grade oncocytic tumor of kidney harboring TSC/MTOR mutation: clinicopathologic, immunohistochemical and molecular characteristics support a distinct entityVirchows Archiv, 2022
- Co-existence of ESC-RCC, EVT, and LOT as synchronous and metachronous tumors in six patients with multifocal neoplasia but without clinical features of tuberous sclerosis complexHuman Pathology, 2021
- Comparable survival outcome between acquired cystic disease associated renal cell carcinoma and clear cell carcinoma in patients with end-stage renal disease: a multi-institutional central pathology studyPathology, 2021
- Low-Grade Oncocytic Tumor of Kidney (CK7-Positive, CD117-Negative): Incidence in a single institutional experience with clinicopathological and molecular characteristicsHuman Pathology, 2021
- Characterization of a distinct low-grade oncocytic renal tumor (CD117-negative and cytokeratin 7-positive) based on a tertiary oncology center experience: the new evidence from ChinaVirchows Archiv, 2020
- Integrated Molecular Analysis of Papillary Renal Cell Carcinoma and Precursor Lesions Unfolds Evolutionary Process from Kidney Progenitor-Like CellsThe American Journal of Pathology, 2019
- Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease — a contiguous gene syndromeNature Genetics, 1994